Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include always present findings: Reduced antral follicle count, Female infertility, Elevated circulating follicle stimulating hormone level, and Decreased circulating antimullerian hormone circulation; and common findings: Secondary amenorrhea and Oligomenorrhea.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Hormones | 2 | Secondary amenorrhea, Female infertility |
MEIOB encodes meiosis specific with OB-fold (442 aa). Single-stranded DNA-binding protein required for homologous recombination in meiosis I. Highest expression in Testis (74.8 TPM) and Skin Not Sun Exposed Suprapubic (0.5 TPM).
Premature ovarian failure 23 is associated with mutations in the MEIOB gene on chromosome 16.
MEIOB is classified as a druggable target with score 0.0.
Genetic testing for MEIOB is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 4 always present features, 2 common features.
No clinical trials have been registered for premature ovarian failure 23.
53 publications have been identified in PubMed for premature ovarian failure 23. Research spans Epidemiology / Natural History (42%), Review / Meta-Analysis (25%), and Basic Science / Preclinical (19%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 22 | 42% |
Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 3:07 PM UTC
Online Mendelian Inheritance in Man
Lab test results |
1 |
Elevated circulating follicle stimulating hormone level |
Research summaries
13 |
25% |
Laboratory research | 10 | 19% |
Clinical study results | 5 | 9% |
Patient case studies | 2 | 4% |
New treatment approaches | 1 | 2% |
Wang X (2026). [PMID: 41555377](https://pubmed.ncbi.nlm.nih.gov/41555377/). *Reprod Biol Endocrinol*. [Review / Meta-Analysis]
Chen JH (2026). [PMID: 41640848](https://pubmed.ncbi.nlm.nih.gov/41640848/). *Front Public Health*. [Epidemiology / Natural History]
Morbey EJ (2026). [PMID: 42001465](https://pubmed.ncbi.nlm.nih.gov/42001465/). *Hum Reprod*. [Epidemiology / Natural History]
Su H (2026). [PMID: 41940375](https://pubmed.ncbi.nlm.nih.gov/41940375/). *Hum Reprod Open*. [Review / Meta-Analysis]
Benseler A (2026). [PMID: 41774960](https://pubmed.ncbi.nlm.nih.gov/41774960/). *Int J Gynecol Cancer*. [Case Report / Case Series]
Abex P (2026). [PMID: 42056376](https://pubmed.ncbi.nlm.nih.gov/42056376/). *Dermatol Ther (Heidelb)*. [Review / Meta-Analysis]
Cheina S (2026). [PMID: 41453445](https://pubmed.ncbi.nlm.nih.gov/41453445/). *J Gynecol Obstet Hum Reprod*. [Epidemiology / Natural History]
Zhao W (2026). [PMID: 41819944](https://pubmed.ncbi.nlm.nih.gov/41819944/). *Maturitas*. [Epidemiology / Natural History]
Zhu J (2026). [PMID: 41589844](https://pubmed.ncbi.nlm.nih.gov/41589844/). *Menopause*. [Epidemiology / Natural History]
Jafarzade A (2025). [PMID: 40813742](https://pubmed.ncbi.nlm.nih.gov/40813742/). *Reprod Sci*. [Basic Science / Preclinical]